Question explored with the scientific record
Do I need a COVID vaccine
The short version: for a healthy adult or child, the benefit is small and the safety data is incomplete.
The evidence shows the vaccines reduce severe outcomes in older adults and those with risk factors. In Turkey, two mRNA doses cut ICU risk by 99% in people over 65 compared to a single inactivated dose [16]. In Estonia, vaccinated people had a 68% lower risk of death in the year after infection [14]. But these are observational studies, not randomized trials, and the unvaccinated comparison group is never a true placebo.
For healthy children, the math is different. The infection hospitalization rate for children 5-14 is about 1 in a million [4]. Vaccine effectiveness against severe disease in children 5-11 ranges from 41% to 83% depending on the study [4]. Meanwhile, myocarditis after the second mRNA dose in adolescent males runs 6.7 to 15 per 100,000 [4]. The ACIP itself acknowledges safety signals for ischemic stroke after mRNA vaccines in older adults and Guillain-Barre in those 65+ [1].
| Group | Risk from disease | Risk from vaccine | Net benefit |
|---|---|---|---|
| Healthy child 5-14 | ~1 in 1M hospitalized [4] | Myocarditis ~1.8 per 1M under 12 [4] | Small or neutral |
| Adolescent male 16-19 | Low absolute risk | Myocarditis 6.7-15 per 100k [4] | Uncertain |
| Adult over 65 | ~2/3 of COVID hospitalizations [1] | GBS and stroke signals [1] | Moderate |
| Adult under 65 with no risk factors | Low absolute risk | Unknown long-term safety | Not clear |
The long-term safety data does not exist. No trial has compared vaccinated to unvaccinated over years with all-cause mortality as the endpoint. The liability shield means the manufacturer has no market incentive to run that study.
My call: for an older adult or someone with risk factors, the evidence supports vaccination. For a healthy child or young adult, the benefit is too small and the safety data too thin to justify it. Confidence: moderate for older adults, low for everyone else.
Sources examined 20
-
June 2024 ACIP Meeting Update: Influenza, COVID-19, RSV, and Other Vaccines
ACIP's June 2024 meeting update outlines updated US pediatric vaccine recommendations for 2024–2025 across influenza, COVID-19, RSV, and other vaccines, summarizing safety surveillance, emerging vaccine options, and policy changes to broaden access.
DOI: 10.1542/peds.2024-068310 -
Comparative effectiveness of construal-level messaging in the COVID-19 Vaccine Injury Compensation Program in the Republic of Korea: a randomized controlled trial
In a randomized controlled trial among 526 Korean adults, high-level construal framing of messages about the COVID-19 Vaccine Injury Compensation Program (CVICP) produced broader improvements in attitudes toward the program and COVID-19 vaccination than a low-level construal, su…
DOI: 10.24171/j.phrp.2024.0354 -
Understanding the drivers and barriers of elderly vaccination in post-pandemic China: a qualitative study in Shenzhen
A qualitative study conducted in Shenzhen, China, using CMA and IMBP frameworks to uncover multi-level drivers and barriers to elderly vaccination in the post-pandemic era, highlighting how individual beliefs, family/peer influence, trust in health providers and government, poli…
DOI: 10.1186/s12889-025-25437-7 -
Vaccination against COVID-19 — risks and benefits in children
This article provides a narrative review of the risks and benefits of COVID-19 vaccination in children, concluding that while vaccination reduces severe disease and MIS-C, the overall benefits to healthy children are diminished by high prior infection and immunity, transient eff…
DOI: 10.1007/s00431-023-05380-8 -
Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved?
CoronaVac vaccination in Mitú, Colombia's Amazon region markedly reduced COVID-19 mortality and severe disease, with a post-vaccination mortality rate of 0.22% versus 2.2% pre-vaccination and 447 breakthrough infections among 7,849 vaccinees (5.7%), indicating strong protection …
DOI: 10.1186/s40794-021-00159-x -
Overview of COVID-19 vaccine adverse events
This is a narrative review that compiles and classifies the most significant adverse events reported for COVID-19 vaccines, comparing safety across platforms and summarising Poland-specific pharmacovigilance data to illustrate the overall positive benefit–risk balance of vaccina…
DOI: 10.32383/appdr/195110 -
Efficacy of COVID-19 Vaccine
A comprehensive synthesis of published COVID-19 vaccine efficacy across multiple platforms and regimens shows strong protection overall but variability by vaccine type and dosing schedule.
DOI: 10.3329/jopsom.v40i2.61799 -
Pediatric Rotavirus Hospitalization Rates in the Military Health System Before and During the COVID-19 Pandemic
A population-level, monthly cross-sectional study in the US Military Health System examining rotavirus vaccination and hospitalization rates before and during the COVID-19 pandemic, finding declines in vaccination and hospitalizations in the early pandemic years with a rebound t…
DOI: 10.3390/vaccines13050492 -
Imbalanced salivary electrolytes, COVID-19 severity, and dysgeusia
COVID-19 markedly reduces unstimulated saliva volume, pH, zinc, and major salivary electrolytes (Na+, K+, Ca++), with greater depletion in severe disease, while dysgeusia shows no clear association with these salivary changes, suggesting saliva-based markers could aid early diag…
DOI: 10.22514/sv.2023.005 -
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
This study evaluates the effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection and COVID-19 severity in Galicia, Spain, demonstrating high vaccine effectiveness across various age groups and significant reductions in hospitalization, ICU admission, and mortality.
DOI: 10.3390/ijerph19074039 -
Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19: A Multicenter, Double-Blinded, Randomized-Controlled Trial (PLATEAU Study)
A multicenter, double-blind randomized controlled trial in Nagasaki, Japan found that daily LC-Plasma (heat-killed Lactococcus lactis) did not improve overall eight-symptom severity in mild COVID-19 over 14 days, but post-hoc analyses suggested faster recovery of smell/taste dis…
DOI: 10.1007/s40121-025-01246-8 -
Heme, Heme Oxygenase-1, Statins, and SARS-CoV-2
This article discusses how heme and the inducible heme oxygenase-1 (HO-1) pathway maintain redox balance, reviews evidence that HO-1 upregulation—potentially via statins or other inducers—may mitigate SARS-CoV-2 severity, and highlights genetic, animal-model, and observational d…
DOI: 10.3390/antiox12030614 -
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
Delivery of a SARS-CoV-2 spike DNA vaccine by jet injection induces neutralizing antibodies and protects both wild-type and cyclophosphamide-immunosuppressed Syrian hamsters from SARS-CoV-2 infection and disease.
DOI: 10.1038/s41541-020-00279-z -
Dynamic effects of COVID-19 vaccination on major acute cardiovascular events and mortality following SARS-CoV-2 infection in a target trial emulation study
In a population-based Estonian cohort, this target-trial emulation study shows that pre-infection COVID-19 vaccination modestly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality within the year after SARS-CoV-2 infection, with the protective …
DOI: 10.1038/s41598-025-13043-x -
The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada
A public-health economics analysis in Canada evaluating the public health impact and cost-effectiveness of Moderna's next-generation COVID-19 vaccine mRNA-1283 compared with no vaccination and with current vaccines, finding substantial reductions in infections, hospitalizations,…
DOI: 10.1080/13696998.2025.2549630 -
Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines
This retrospective cohort study of 24,538 PCR-confirmed COVID-19 patients in Türkiye found that two-dose mRNA vaccines, whether homologous or heterologous, provided the strongest and most durable protection against severe outcomes, while inactivated vaccines offered significant …
DOI: 10.3855/jidc.21743 -
Long COVID prevalence and impact on quality of life 2 years after acute COVID-19
In a Korean adult cohort, long COVID symptoms persisted up to 24 months with neuropsychiatric effects remaining prominent, and post-infection vaccination did not significantly reduce long COVID prevalence despite high vaccination uptake.
DOI: 10.1038/s41598-023-36995-4 -
An Experimental Measurement Through Folk Therapy to Strengthen the Immunity After Confirmed COVID-19
Folk therapy applied to adults recovering from COVID-19 is associated with reduced residual cough and improved subjective immunity, based on a 92-participant before-and-after analysis.
DOI: 10.47750/pnr.2022.13.s06.241 -
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
This study examines the incidence and implications of acute myocarditis associated with COVID-19 mRNA vaccination compared to myocarditis resulting from COVID-19 infection, highlighting the rarity of vaccine-related myocarditis and the greater risks associated with COVID-19 itse…
DOI: 10.1038/s41569-021-00662-w -
Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy
This cohort study in Lombardy, Italy, assesses the increased risk of myocarditis and pericarditis associated with COVID-19 vaccination, particularly highlighting the higher incidence in young men after receiving the Moderna vaccine, while also demonstrating that the benefits of …
DOI: 10.1186/s12879-022-07823-3